Current and emerging therapy for improving outcomes in patients with intraocular retinoblastoma

Rachel C. Brennan, Eleanor M. Pritchard, R. Kiplin Guy, Michael A. Dyer, Matthew Wilson

Research output: Contribution to journalReview article

Abstract

Introduction: Survival for patients with intraocular retinoblastoma (RB) is excellent. Over the past two decades, the focus of therapy has shifted to emphasize ocular salvage and vision preservation. The combination of chemoreduction and aggressive focal therapies has formed the new standard approach to most patients with advanced intraocular RB. However, seeding of the vitreous cavity continues to be the primary reason for treatment failure in these patients.Areas covered: Local delivery methods, including periocular injections, intra-ophthalmic artery infusions, and intravitreal injections, have been developed in the hope of controlling disease in advanced cases. This review highlights the current approach to therapy for patients and discusses these new local delivery techniques and the discovery of novel therapeutics that may help to further improve ocular outcomes for patients with intraocular RB.Expert opinion: Due to the rarity of this childhood disease, clinical efforts to improve ocular salvage and vision preservation must occur in parallel with translational research efforts that identify novel strategies for therapy of RB. A dedicated RB team provides guidance for a coordinated approach to address the key therapeutic, biologic, and long-term challenges in our patients.

Original languageEnglish (US)
Pages (from-to)1155-1166
Number of pages12
JournalExpert Opinion on Orphan Drugs
Volume3
Issue number10
DOIs
StatePublished - Oct 3 2015

Fingerprint

Retinoblastoma
Therapeutics
Intraocular Injections
Ophthalmic Artery
Intravitreal Injections
Translational Medical Research
Expert Testimony
Treatment Failure
Survival

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

Current and emerging therapy for improving outcomes in patients with intraocular retinoblastoma. / Brennan, Rachel C.; Pritchard, Eleanor M.; Guy, R. Kiplin; Dyer, Michael A.; Wilson, Matthew.

In: Expert Opinion on Orphan Drugs, Vol. 3, No. 10, 03.10.2015, p. 1155-1166.

Research output: Contribution to journalReview article

Brennan, Rachel C. ; Pritchard, Eleanor M. ; Guy, R. Kiplin ; Dyer, Michael A. ; Wilson, Matthew. / Current and emerging therapy for improving outcomes in patients with intraocular retinoblastoma. In: Expert Opinion on Orphan Drugs. 2015 ; Vol. 3, No. 10. pp. 1155-1166.
@article{48ddc18e47a146c39c775befc77a8ea4,
title = "Current and emerging therapy for improving outcomes in patients with intraocular retinoblastoma",
abstract = "Introduction: Survival for patients with intraocular retinoblastoma (RB) is excellent. Over the past two decades, the focus of therapy has shifted to emphasize ocular salvage and vision preservation. The combination of chemoreduction and aggressive focal therapies has formed the new standard approach to most patients with advanced intraocular RB. However, seeding of the vitreous cavity continues to be the primary reason for treatment failure in these patients.Areas covered: Local delivery methods, including periocular injections, intra-ophthalmic artery infusions, and intravitreal injections, have been developed in the hope of controlling disease in advanced cases. This review highlights the current approach to therapy for patients and discusses these new local delivery techniques and the discovery of novel therapeutics that may help to further improve ocular outcomes for patients with intraocular RB.Expert opinion: Due to the rarity of this childhood disease, clinical efforts to improve ocular salvage and vision preservation must occur in parallel with translational research efforts that identify novel strategies for therapy of RB. A dedicated RB team provides guidance for a coordinated approach to address the key therapeutic, biologic, and long-term challenges in our patients.",
author = "Brennan, {Rachel C.} and Pritchard, {Eleanor M.} and Guy, {R. Kiplin} and Dyer, {Michael A.} and Matthew Wilson",
year = "2015",
month = "10",
day = "3",
doi = "10.1517/21678707.2015.1075878",
language = "English (US)",
volume = "3",
pages = "1155--1166",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Current and emerging therapy for improving outcomes in patients with intraocular retinoblastoma

AU - Brennan, Rachel C.

AU - Pritchard, Eleanor M.

AU - Guy, R. Kiplin

AU - Dyer, Michael A.

AU - Wilson, Matthew

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Introduction: Survival for patients with intraocular retinoblastoma (RB) is excellent. Over the past two decades, the focus of therapy has shifted to emphasize ocular salvage and vision preservation. The combination of chemoreduction and aggressive focal therapies has formed the new standard approach to most patients with advanced intraocular RB. However, seeding of the vitreous cavity continues to be the primary reason for treatment failure in these patients.Areas covered: Local delivery methods, including periocular injections, intra-ophthalmic artery infusions, and intravitreal injections, have been developed in the hope of controlling disease in advanced cases. This review highlights the current approach to therapy for patients and discusses these new local delivery techniques and the discovery of novel therapeutics that may help to further improve ocular outcomes for patients with intraocular RB.Expert opinion: Due to the rarity of this childhood disease, clinical efforts to improve ocular salvage and vision preservation must occur in parallel with translational research efforts that identify novel strategies for therapy of RB. A dedicated RB team provides guidance for a coordinated approach to address the key therapeutic, biologic, and long-term challenges in our patients.

AB - Introduction: Survival for patients with intraocular retinoblastoma (RB) is excellent. Over the past two decades, the focus of therapy has shifted to emphasize ocular salvage and vision preservation. The combination of chemoreduction and aggressive focal therapies has formed the new standard approach to most patients with advanced intraocular RB. However, seeding of the vitreous cavity continues to be the primary reason for treatment failure in these patients.Areas covered: Local delivery methods, including periocular injections, intra-ophthalmic artery infusions, and intravitreal injections, have been developed in the hope of controlling disease in advanced cases. This review highlights the current approach to therapy for patients and discusses these new local delivery techniques and the discovery of novel therapeutics that may help to further improve ocular outcomes for patients with intraocular RB.Expert opinion: Due to the rarity of this childhood disease, clinical efforts to improve ocular salvage and vision preservation must occur in parallel with translational research efforts that identify novel strategies for therapy of RB. A dedicated RB team provides guidance for a coordinated approach to address the key therapeutic, biologic, and long-term challenges in our patients.

UR - http://www.scopus.com/inward/record.url?scp=84942553000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942553000&partnerID=8YFLogxK

U2 - 10.1517/21678707.2015.1075878

DO - 10.1517/21678707.2015.1075878

M3 - Review article

VL - 3

SP - 1155

EP - 1166

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 10

ER -